CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
infusion of NMDA antagonistdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02373124
NCT02373124Phase 2Completed
CompareCT.gov

Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial

New York State Psychiatric Institute·interventional·Posted Feb 26, 2015·Updated Feb 5, 2020

In Brief

A Phase 2 clinical trial evaluating infusion of NMDA antagonist for Cocaine Use Disorders. Completed, enrolled 4 participants across 1 site.

Detailed Summary

This study evaluates the feasibility of a treatment paradigm that involves naturalistic cocaine use opportunities in the context of psychotherapy aimed at utilizing these opportunities therapeutically.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Use Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 26, 2015
Enrollment StartDec 1, 2014
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.3 years ago

Interventions

infusion of NMDA antagonistdrug

52 minute infusion